Hhlr Advisors LTD. Sells 1,561,921 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Hhlr Advisors LTD. lowered its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 49.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,582,635 shares of the company’s stock after selling 1,561,921 shares during the quarter. Kiniksa Pharmaceuticals comprises 0.9% of Hhlr Advisors LTD.’s portfolio, making the stock its 14th largest holding. Hhlr Advisors LTD.’s holdings in Kiniksa Pharmaceuticals were worth $39,550,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC boosted its position in shares of Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares during the period. nVerses Capital LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $80,000. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at approximately $71,000. Ashton Thomas Private Wealth LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the second quarter valued at approximately $100,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $189,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA stock opened at $22.08 on Friday. The stock has a market cap of $1.59 billion, a P/E ratio of -157.70 and a beta of 0.35. Kiniksa Pharmaceuticals, Ltd. has a one year low of $15.82 and a one year high of $28.15. The stock has a fifty day moving average price of $24.02 and a 200 day moving average price of $22.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s revenue for the quarter was up 67.4% compared to the same quarter last year. During the same period last year, the business earned ($0.20) earnings per share. Equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the completion of the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at $2,923,205.25. This represents a 13.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This represents a 53.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 95,192 shares of company stock worth $2,479,390 over the last three months. 54.57% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Evercore ISI increased their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.